At Imbria, our mission is to translate our understanding of cellular metabolism into medicines that improve the lives of patients with limited or inadequate treatment options.
Developing new treatments for cardiometabolic disorders
Patients & Physicians
Turning our knowledge of cellular metabolism into new medicines that improve the lives of patients
Latest news
Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24
Read moreApril 08, 2024
ACC.24 Late-Breaking IMPROVE-HCM Presentation
April 08, 2024